Delivery Order SPE2DB24D2205-SPE2DB25FEEYG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $1,269.76. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for ultimate completion by November 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $2,328.26 on December 1, 2025, with ultimate completion scheduled for December 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml), valued at $1,234.22. This competitively awarded, non-set-aside delivery order represents a firm fixed-price transaction with an ultimate completion date of December 31, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,218.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities, with performance completion scheduled for November 4, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,491.42 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) on November 10, 2025, with an ultimate completion date of November 12, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and will be performed at the contractor's location in Conshohocken, Pennsylvania. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $1,809.72. This is a firm fixed-price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) on September 10, 2025, with a ceiling value of $1,953.55. This is a firm fixed-price delivery order with no set-aside designation, indicating that the award was competitively procured. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml oral suspension (180ml) on December 2, 2025, with a ceiling value of $1,208.98. This firm fixed-price delivery order is scheduled for completion by December 3, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $1,139.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for Quillivant XR 25 mg/5 ml suspension (60 ml), with an ultimate completion date of December 12, 2025. This non-set-aside delivery order is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's Indefinite Delivery Contract (IDC) with...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEEYGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,079.82. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 17, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company maintains an extensive portfolio of pharmaceutical deliveries encompassing brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This specific delivery order for Quillivant XR, an attention-deficit/hyperactivity disorder medication, represents a routine transaction within AmerisourceBergen's established relationship with DLA and demonstrates the company's ongoing role in supplying essential pharmaceuticals to support federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 7/16/25 |